Teva Raises $2.1 Billion in Debt Tender Offer | Ctech
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024 | Business Wire
Teva to axe 14,000 jobs despite uproar in Israel | Financial Times
Teva CEO reportedly wanted to stay in his job | The Times of Israel
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
Credit Rating Process | A Complete Beginner's Guide
Credit Rating Process | A Complete Beginner's Guide
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
Teva Reports Third Quarter 2021 Financial Results
Teva Nailed With S&P Downgrade - TheStreet
S&P downgrades Teva, pushing credit rating further into junk territory - Business - Haaretz.com
Moody's Downgrades Teva Bond Rating to “Junk” | Ctech
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Sell Teva Pharmaceutical due to increasing generic drugs competition: Credit Suisse
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report | Business Wire
CSRWire - Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
